iBio announces anthrax vaccine patent

iBio, Inc., a developer of biologics-related technology, announced the issuance on Wednesday of a U.S. patent that covers compositions of matter and methods of formulating and producing vaccines for anthrax.

U.S. Patent 8,277,816, entitled "Bacillus Anthracis Antigens, Vaccines, Compositions and Related Methods," is based on an invention created by researchers at the Fraunhofer USA Center for Molecular Biotechnology. The facility is an iBio research collaborator.

"This new patent broadens protected uses of iBio's proprietary iBioLaunch platform and also expands the company's portfolio of assets relevant to bio-defense applications, such as our successful preclinical vaccine for plague and a proprietary antibody for anthrax," Terence Ryan, iBio's chief scientific officer, said. "There should be significant interest in these opportunities from potential commercial collaborators focused on infectious disease and bio-defense markets."

A proprietary antibody produced with iBio's proprietary iBioLaunch technology demonstrated protection of non-human primates from anthrax spores, according to data published in peer-reviewed scientific journals. A proprietary vaccine incorporating the company's iBioModulator technology was found to protect non-human primates from pneumonic plague.

iBio, Inc. said that its iBioLaunch and iBioModulator platforms have multiple advantages over other antibody creation systems. The purported advantages include significantly lower capital and operating costs for comparable production, product entry unconstrained by traditional process patents, unlimited surge capacity for remedial action against pandemic disease and bioterrorism, success with proteins that are difficult or impossible to produce with other methods, broad applications to biologics and a significantly shorter production time.